Because of the virus infection depend on ACE2, pharmacological manipulation of the RAS through angiotensin converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), and soluble recombinant ACE2 proteins administration have been discussed as a potential therapy for COVID-19 (Batlle et al., 2020; South et al., 2020). This evidence concerns the gene ACE and COVID-19.